Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg 80€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  2. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  3. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  4. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  5. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  6. Liu J, et al. 2019. Immunity. 50:600. PubMed
  7. Milanovic M, et al. 2021. Cancer Res. 81:426. PubMed
  8. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  9. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  10. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  11. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  12. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  13. Chowdhury S, et al. 2022. Cancer Res. 82:2640. PubMed
  14. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  15. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  16. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  17. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  18. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  19. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  20. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  21. Ding L, et al. 2023. J Clin Invest. 133: . PubMed
  22. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  23. Wang L, et al. 2022. Nutrients. 15: . PubMed
  24. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  25. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  26. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  27. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  28. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  29. Milanovic M, et al. 2021. J Immunol. 206:1228. PubMed
  30. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  31. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  32. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  33. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  34. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  35. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  36. Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed
  37. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  38. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  39. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  40. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  41. Ma X, et al. 2023. Nat Commun. 14:1606. PubMed
  42. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  43. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  44. Bhatia V, et al. 2023. Nat Commun. 14:2041. PubMed
  45. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  46. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  47. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  48. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  49. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  50. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  51. Pagano G, et al. 2023. Haematologica. . PubMed
  52. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  53. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  54. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  55. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  56. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  57. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  58. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  59. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  60. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  61. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  62. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  63. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  64. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  65. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  66. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  67. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  68. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  69. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  70. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  71. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  72. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  73. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  74. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  75. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  76. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  77. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  78. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  79. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  80. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  81. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  82. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  83. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  84. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  85. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  86. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  87. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  88. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  89. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  90. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  91. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  92. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  93. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  94. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  95. Morales D, et al. 2015. J Virol. 89:337. PubMed
  96. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  97. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  98. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  99. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  100. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  101. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  102. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  103. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  104. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  105. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  106. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  107. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  108. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  109. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  110. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  111. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  112. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  113. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  114. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  115. Wu J, et al. 2020. Immunity. 53:115. PubMed
  116. Köchl R, et al. 2020. Elife. 9:00. PubMed
  117. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  118. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  119. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  120. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  121. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  122. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  123. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  124. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  125. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  126. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  127. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  128. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  129. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  130. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  131. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  132. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  133. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  134. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  135. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  136. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  137. Yang J, et al. 2020. Nature. 586:572. PubMed
  138. Wan X, et al. 2018. Nature. 560:107. PubMed
  139. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  140. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  141. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  142. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  143. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  144. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  145. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  146. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  147. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  148. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  149. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  150. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  151. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  152. Du J, et al. 2018. AMB Express. 8:158. PubMed
  153. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  154. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  155. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  156. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  157. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  158. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  159. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  160. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  161. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  162. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  163. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  164. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  165. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  166. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  167. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  168. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  169. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  170. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  171. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  172. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  173. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  174. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  175. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  176. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  177. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  178. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  179. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  180. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  181. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  182. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  183. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  184. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  185. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  186. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  187. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  188. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  189. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  190. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  191. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  192. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  193. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  194. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  195. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  196. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  197. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  198. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  199. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  200. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  201. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  202. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  203. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  204. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  205. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  206. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  207. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  208. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  209. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  210. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  211. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  212. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  213. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  214. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  215. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  216. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  217. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  218. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  219. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  220. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  221. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  222. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  223. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  224. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  225. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  226. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  227. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  228. Li H, et al. 2022. iScience. 25:104481. PubMed
  229. Wang X, et al. 2022. Elife. 11:. PubMed
  230. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  231. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  232. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  233. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  234. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  235. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  236. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  237. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  238. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  239. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  240. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  241. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  242. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  243. Xie L, et al. 2020. Infect Immun. :88. PubMed
  244. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  245. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  246. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  247. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  248. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  249. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  250. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  251. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  252. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Spark YG™ 581 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark YG™ 593 anti-mouse CD8a (Flexi-Fluor™) Antibody 53-6.7 FC
StarBright UltraViolet 795 anti-mouse CD8a 53-6.7 FC
StarBright UltraViolet 575 anti-mouse CD8a 53-6.7 FC
Spark PLUS V475™ anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account